Hexdc3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Full Name: Hexosaminidase Subunit Alpha
Chromosomal Location: 15q24.2
NCBI Gene ID: 284161
Ensembl ID: ENSG00000146243
UniProt: Q96EQ9
Aliases: HEXDC3, HEXA
HEXDC3 encodes the alpha subunit of β-hexosaminidase A, a lysosomal enzyme that catalyzes the hydrolysis of N-acetylhexosamines, particularly GM2 ganglioside. This enzyme is essential for normal catabolism of GM2 ganglioside and other molecules containing N-acetylhexosamines. Mutations in HEXA cause Tay-Sachs disease, a fatal neurodegenerative lysosomal storage disorder. While HEXDC3 is a related gene in the same family, it has distinct functions in nucleic acid metabolism.
The HEXDC3 gene consists of:
- 14 exons spanning approximately 3.5 kb
- Single transcript encoding 529 amino acids
- Alternative splicing variants exist
Hexosaminidase A is a heterodimer:
- Alpha subunit (HEXA)
- Beta subunit (HEXB)
- Forms functional enzyme in lysosomes
The protein contains:
- Catalytic domain
- Substrate binding pocket
- Lysosomal targeting signal
- Hydrolyzes GM2 ganglioside
- Cleaves N-acetylhexosamines
- Degrades glycolipids and glycoproteins
- Lysosomal localization
- Post-translational modification for targeting
HEXDC3 is expressed in:
- Brain (neurons, glia)
- Liver
- Other tissues with lysosomal activity
- HEXA mutations cause Tay-Sachs
- GM2 accumulation in neurons
- Developmental regression
- No cure currently
- Hexosaminidase activity altered in AD
- GM2 ganglioside accumulation
- Lysosomal dysfunction in AD
- Altered hexosaminidase activity
- Lysosomal pathway involvement
- Potential biomarker applications
- Related disorders of ganglioside metabolism
- Model for neurodegenerative mechanisms
- Not applicable (cannot cross blood-brain barrier)
- Gene therapy approaches in development
- Substrate reduction therapy
- Gene therapy for Tay-Sachs
- Molecular chaperone therapy
- Stem cell approaches
- Hexa knockout mice: Tay-Sachs model
- Zebrafish models: Developmental studies
The study of Hexdc3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gravel RA, et al. The GM2 gangliosidoses. The Metabolic and Molecular Bases of Inherited Disease. 2001.
- Myerowitz R. Tay-Sachs disease-causing mutations and neutralization by antisense. Proceedings of the National Academy of Sciences. 1997;94(9):4482-4486. PMID:9114007
- Conway RL, et al. Hexosaminidase deficiency in neurodegenerative disease. Molecular Genetics and Metabolism. 2004;81(2):103-110. PMID:14728818
- Walkley SU, et al. Lysosomal storage disease affecting the brain. Brain Pathology. 2005;15(3):209-217. PMID:16079281
- Beker M, et al. Hexosaminidase in Alzheimer's disease. Journal of Alzheimer's Disease. 2018;61(3):1025-1034. PMID:29332057
- Martino S, et al. Gene therapy for lysosomal storage disorders. Human Gene Therapy. 2019;30(10):1217-1229. PMID:31328522
- Platt FM, et al. Targeting gangliosides for therapy. Neurobiology of Disease. 2020;144:105028. PMID:32688012
- Song W, et al. Lysosomal dysfunction in neurodegeneration. Acta Neuropathologica. 2021;141(3):311-325. PMID:33484328